Background: Postmenopausal women who use hormone-replacement therapy (HRT) containing oestrogen alone are at increased risk of endometrial cancer. To minimise this risk, many HRT users who have not had a hysterectomy use combined oestrogen-progestagen preparations or tibolone. Limited information is available on the incidence of endometrial cancer in users of these therapies. Methods: 716 738 postmenopausal women in the UK without previous cancer or previous hysterectomy were recruited into the...[Show more]
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.